Best compounded tirzepatide telehealth in 2026

The short answer

Six telehealth services prescribe compounded tirzepatide direct to patients today. RxPepsDirect has the lowest price ($45 per 12mg starter vial plus a one-time $39 visit) in 29 jurisdictions. Mochi Health is the cheapest national option at $169 to $278 a month all-in and now covers all 50 states. Eden is $298 a month after a $238 first month, covers all 50 states, and runs its own compounding pharmacy. Henry Meds sells tirzepatide only as an oral tablet, at about $349 to $449 a month, which puts its top tier level with a Zepbound vial from Lilly. Aspire Health and Nava Health round out the field with narrower footprints and pricing you only see after a consult. The bigger change since our last check is on the brand side: Zepbound vials are $299 to $449 cash, and the new GLP-1 pills start at $149, so the old “80 to 90 percent cheaper” claim no longer holds at every dose.

How we built this comparison

We re-checked every site on September 8, 2026. To make the list, a service has to prescribe compounded tirzepatide to patients through a US 503A pharmacy and take cash-pay. Branded tirzepatide (Zepbound, Mounjaro) is a different product and is not counted, though we now use it as the price benchmark. Effective monthly cost is what the patient pays end-to-end: membership or visit fee plus medication. Where a service publishes no price we say so instead of guessing. To compare the 503A pharmacies that actually fill these prescriptions, see our ranking of the best tirzepatide compounding pharmacy.

Side-by-side comparison

RxPepsDirect first month assumes the 12mg starter vial, which covers four weeks at 1.5mg twice weekly. Mochi and Eden medication prices are the vendors’ published figures; Henry Meds says only that its GLP-1 plans start at $179 a month, so the tirzepatide range comes from 2026 reviews of its program page.

What the brand names cost now

The savings argument for compounded tirzepatide used to be simple: Mounjaro and Zepbound listed above $1,000 a month and nothing cheaper existed without insurance. That changed on December 1, 2025, when Lilly cut Zepbound single-dose vials on LillyDirect to $299 for 2.5mg, $399 for 5mg, and $449 for 7.5mg through 15mg. The same vial prices are listed on TrumpRx. The pen list price is still roughly $1,087 a month, and Mounjaro (the diabetes label of the same molecule) has no self-pay vial program, so the Zepbound vial is the number compounded has to beat.

Two more brand options arrived on the semaglutide side. Novo Nordisk’s self-pay Wegovy pens are $199 a month for the first two fills of the 0.25mg and 0.5mg starter doses (an offer that runs through December 31, 2026), then $349 a month for standard doses and $399 for the 7.2mg high dose. The Wegovy pill is $149 a month for 1.5mg, $199 for 4mg, and $299 for 9mg and 25mg. Lilly’s orforglipron pill, sold as Foundayo, was approved by the FDA on April 1, 2026 and sells for $149 (0.8mg) to $349 (17.2mg) a month on LillyDirect. Neither pill is tirzepatide, but both compete for the same cash-pay patient.

The savings math, rebuilt

Compounded tirzepatide at RxPepsDirect is paid to Optimal Balance Pharmacy at wholesale: $45 for a 12mg vial, $90 for 24mg, $127.50 for 34mg, $165 for 44mg, $210 for 56mg, and $247.50 for 66mg, plus a $39 medical visit per order. On a four-week month, a vial that covers your weekly dose compares to the Zepbound vial like this:

Add the $39 visit and the first month at the starter dose is $84 against $299, a 72 percent saving. The gap is widest at the start and narrowest at the top of the ladder, where a 66mg vial is $247.50 against a $449 brand vial. The bundled services tell a different story: Henry Meds at up to $449 a month costs the same as the Zepbound vial, and Eden at $298 or Mochi at up to $278 are within $150 of it. If a bundle is the only compounded option in your state, price the brand vial before you sign up.

1. RxPepsDirect

Best for: the lowest cash price on a per-vial basis. $45 for a 12mg starter vial, $39 for the medical visit, pharmacy bills you at wholesale.

RxPepsDirect is a Denver, Colorado-based telehealth service that partners with Optimal Balance Pharmacy (Texas 503A). Tirzepatide comes in two formulations: Tirzepatide/B-12 from $45/12mg and Tirzepatide/Glycine from $225/60mg for patients who react to B-12. Both use the same active molecule as Zepbound and Mounjaro. The full titration ladder is published on the product page so patients can plan the cost as the dose goes up.

RxPepsDirect is the only service on this list that doesn’t bundle. You pay $39 once for the medical visit; that’s it from the clinic. Optimal Balance bills you separately for the medication, at wholesale, with no clinic markup. There’s no subscription and no membership tier.

• Price ladder: $45 (12mg), $90 (24mg), $127.50 (34mg), $165 (44mg), $210 (56mg), $247.50 (66mg), Tirzepatide/B-12, paid to the pharmacy at wholesale
• Medical visit: $39 one-time per order
• Where it prescribes: 29 jurisdictions, 28 states plus the District of Columbia (medical director: Dr. Jonathan Snipes, NPI 1821250077)
• Pharmacy: Optimal Balance Pharmacy (503A, Texas)
• Lab testing: Eagle Analytical (sterility via ScanRDI or Celsis, endotoxin per USP <85>, plus potency per USP <621> on select batches)
• Carrier options: B-12 (cyanocobalamin) or glycine

The trade-off: 29-jurisdiction coverage is narrower than Eden or Mochi (50 states each) or Henry Meds (about 40). If RxPepsDirect does not yet prescribe in your state, Mochi is the next-cheapest option. Tirzepatide/B-12 product page or read how compounded tirzepatide compares to the branded versions. For the wider field of prescription peptide services, see our ranking of the best peptide companies and the best telehealth for compounded peptides comparison.

2. Mochi Health

Best for: the cheapest all-in monthly price with national coverage, plus dietitian and program support bundled into the membership.

Mochi Health is GLP-1-first and has changed the most since our last check. It moved from flat monthly pricing to per-dose pricing: compounded tirzepatide now runs $90 to $199 a month depending on the dose your provider prescribes, on top of a $79 monthly membership ($39 for the first month). That puts the effective cost at $169 to $278 a month, down from a flat $278. The membership covers registered dietitians, lab review, and ongoing provider check-ins.

The geography problem is gone too. Mochi now advertises service in all 50 states and DC, though it notes that medication availability and promotional pricing vary by state. The pharmacy partner is not named publicly. Eli Lilly sued Mochi in April 2025 over its compounded tirzepatide marketing; that case is still open (see the legal section below).

• Effective monthly cost: $169 to $278 ($79 membership plus $90 to $199 tirzepatide, by dose)
• States: 50 plus DC; availability and promos vary by state
• Pharmacy: Partner 503A pharmacy (not named publicly)
• Bundle includes: medication, programming, dietitian access, lab review

3. Eden

Best for: a flat medication price that does not rise with your dose, national coverage, and a service that owns its own compounding pharmacy.

Eden now publishes its tirzepatide price: $199 a month for the medication, held flat at every dose, plus a membership of $39 for the first month and $99 a month after that. That is $238 the first month and $298 on renewal. Eden serves GLP-1 patients in all 50 states. In August 2025 the company acquired Contigo Compounding, a 503A pharmacy, which now fills Eden prescriptions in-house and gives it control over micro-titration doses and turnaround.

The trade-off is the membership. The $99 renewal fee is a third of the monthly total, and it is charged whether or not your dose changed that month. For a patient on a high dose, Eden’s flat $199 is the best bundled deal on this list; at the starter dose, RxPepsDirect or Mochi are cheaper. Detailed RxPepsDirect vs Eden comparison.

• Effective monthly cost: $238 first month, $298 after ($199 medication plus $99 membership)
• States: 50
• Pharmacy: Contigo Compounding (in-house, acquired August 2025)
• Bundle includes: medication, provider visits, member portal, expedited shipping

4. Henry Meds

Best for: patients who want one flat charge covering medication, visits, supplies, and shipping, and are willing to pay brand-vial money for it.

Henry Meds is one of the largest compounded GLP-1 telehealth services in the US, and the price most people associate with it, “from $179 a month,” is its semaglutide program. Tirzepatide is a different tier and a different form: Henry sells it only as a compounded oral dissolving tablet, at about $349 to $449 a month depending on dose, with everything (medication, provider visits, supplies, shipping) included. Henry does not offer injectable tirzepatide and does not publish tirzepatide pricing on its public site; those figures come from 2026 reviews of its program page and can move.

At its $449 tier, Henry’s oral tirzepatide costs the same as a 7.5mg-and-up Zepbound vial from LillyDirect. The bundle is real, but the price advantage over brand is gone at that tier. Coverage is about 40 states plus DC; Henry is not available in AL, AK, AR, HI, LA, MS, SC, TN, or WV. Henry is also one of the four telehealth companies Eli Lilly sued in April 2025.

• Effective monthly cost: about $349 to $449 by dose, for compounded oral tirzepatide tablets (no injectable)
• States: about 40 plus DC (excludes AL, AK, AR, HI, LA, MS, SC, TN, WV)
• Pharmacy: Partner 503A pharmacy (not named publicly)
• Bundle includes: medication, visits, supplies, shipping

5. Aspire Health

Best for: patients in the upper Midwest and Plains states who want tirzepatide and other peptides under one provider.

Aspire Health is a Nebraska-based telehealth service that prescribes compounded tirzepatide alongside a peptide and “health enhancement” menu. Its tirzepatide page names 13 states (Florida, Arizona, Hawaii, Idaho, Illinois, Iowa, Maine, Minnesota, Nebraska, Oklahoma, South Dakota, Wisconsin, Colorado) and says “and more,” so confirm your state on the consult. Pricing is not on the public site; the intake flow gates it behind a health assessment.

• Effective monthly cost: not published
• States: 13 named, “and more”
• Pharmacy: partner 503A pharmacy (not named publicly)
• Bundle includes: tirzepatide plus other peptides under one clinician

6. Nava Health

Best for: patients near the Virginia or Maryland clinics who want in-person visits as part of their tirzepatide program.

Nava Health prescribes tirzepatide and semaglutide alongside a broader peptide formulary (BPC-157, TB-500, IGF-1 LR3, sermorelin, tesamorelin, ipamorelin, Semax, Selank, GHK-Cu, thymosin alpha-1). The brick-and-mortar clinics are in Ashburn (VA), Fairfax (VA), Bethesda (MD), and Columbia (MD); the telehealth arm covers 15 states: AZ, CO, DC, DE, FL, GA, IL, MD, NC, NJ, NY, PA, TX, VA, and WV. Pricing is consultation-gated.

• Effective monthly cost: consultation-gated
• States: 15
• Pharmacy: “compounding pharmacies” (not named)
• Bundle includes: tirzepatide plus 10 other peptides plus in-person visits where available

Why Ro, Hims, and Calibrate aren’t on this list

You’ll see these names searching for tirzepatide telehealth. They route patients to branded Zepbound and Mounjaro (through insurance or the LillyDirect vial program) rather than compounded tirzepatide, which is a different product and a different price tier. If your insurance covers branded GLP-1s, services like Ro, Calibrate, Form Health, Hone Health, Sesame Care, and PlushCare will usually be cheaper than compounded. If it doesn’t, compare the $299 to $449 Zepbound vial against the compounded prices above before you decide. Each company’s current offering changes quickly, so verify against their live site.

Where the FDA and the courts stand (September 2026)

The legal footing for compounded tirzepatide has not changed in kind since 2025, but the pressure has increased. The facts that matter:

• 503B mass compounding is over. The FDA declared the tirzepatide shortage resolved in December 2024, and enforcement discretion for 503B outsourcing facilities ended on March 19, 2025. On April 30, 2026 the agency went a step further and proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list outright, finding no clinical need for outsourcing facilities to compound them from bulk powder. The comment period closed June 29, 2026. As of this update the rule is not final.
• Marketing is under scrutiny. On March 3, 2026 the FDA announced warning letters to 30 telehealth companies over compounded GLP-1 marketing, citing claims that implied the compounded product was the same as the FDA-approved drug and branding that obscured which pharmacy actually made it.
• The manufacturers are still in court. Eli Lilly sued Mochi Health, Henry Meds, Fella Health, and Willow Health in April 2025 over compounded tirzepatide, and Novo Nordisk has a patent suit against Hims & Hers over compounded semaglutide. On August 6, 2026 a federal judge in Texas dismissed an antitrust suit that a compounding pharmacy had brought against Lilly and Novo. None of these rulings has closed the 503A pathway; they are about how specific companies marketed and produced the drug.
• 503A patient-specific compounding remains legal. A 503A pharmacy can fill a compounded tirzepatide prescription when the prescriber determines and documents that the compounded formulation produces a significant difference for that individual patient. The FDA’s own guidance is explicit that price is not such a difference: “Other factors, such as a lower price, are not sufficient to establish that the compounded drug product is not essentially a copy of the commercially available drug product.” (FDA, Compounded Drug Products That Are Essentially Copies, 503A). In plain terms: cost savings alone is not a valid clinical justification. The documented reason has to be clinical, such as a dose or titration step the branded product does not offer, or a carrier the patient needs. That is what every service on this list depends on, and it is why RxPepsDirect prescribers record the patient-specific reason on each prescription or do not write it.

How common compounded GLP-1 use is now

Gallup’s June 2026 survey of 5,065 US adults, published July 7, 2026, found that 11% of US adults now take a GLP-1 for weight loss, up from 3% in 2024. Among current users, 19% take a compounded version and 12% are not sure which kind they have. Of people who switched from a brand-name drug to a compounded one, 66% cited cost or insurance coverage as the reason. Those numbers explain both sides of this article: the demand for compounded tirzepatide is real and cost-driven, and the brand price cuts described above are aimed squarely at that 19%.

Clinical efficacy and benefits

Liver Fibrosis and Metabolic Dysfunction-Associated Liver Disease

Tirzepatide demonstrates efficacy in improving liver fibrosis in patients with metabolic dysfunction-associated liver disease (MASLD), a common comorbidity in obesity. A 2026 systematic review and network meta-analysis evaluated pharmacotherapies for MASLD patients with fibrosis stages F1 through F3 and found tirzepatide among the effective interventions for reducing fibrosis progression.^[7]

MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), affects approximately 25 to 30% of adults in the United States, with higher prevalence in individuals with obesity and type 2 diabetes. Liver fibrosis represents the pathological accumulation of scar tissue in the liver and is a key determinant of long-term outcomes in MASLD. Fibrosis stages range from F0 (no fibrosis) to F4 (cirrhosis), with F1 through F3 representing progressive scarring without cirrhosis.

The network meta-analysis compared multiple pharmacologic interventions across randomized controlled trials, assessing fibrosis improvement as a primary outcome. Tirzepatide’s dual GLP-1 and GIP receptor agonism appears to confer metabolic benefits beyond glycemic control and weight loss, including improvements in hepatic fat content and inflammatory markers that contribute to fibrosis regression. These findings support tirzepatide as a therapeutic option for patients with obesity-related liver disease, though dedicated prospective trials with biopsy-confirmed endpoints remain important for definitive guidance.

Clinicians prescribing tirzepatide for weight management should consider baseline liver health assessment in appropriate patients, particularly those with elevated liver enzymes or imaging findings suggestive of hepatic steatosis. The reduction in liver fibrosis represents an additional cardiometabolic benefit that may inform treatment selection in patients with multiple obesity-related comorbidities.

How to choose between them

Three questions narrow it down fast:

1. How important is the lowest price? If cost is the deciding factor, RxPepsDirect ($45 starter vial plus $39 visit) is the cheapest path at every dose, and Mochi ($169 to $278 all-in) is the cheapest bundle. Above roughly $300 a month, check the Zepbound vial before you commit to a compounded subscription.
2. How important is state coverage? Eden and Mochi cover all 50 states, Henry Meds about 40, RxPepsDirect 29 jurisdictions. If RxPepsDirect doesn’t prescribe in your state yet, Mochi is usually the answer on price and Eden on dose flexibility.
3. Do you want bundled programming? Mochi’s membership includes a dietitian and structured curriculum; Eden and Henry include visits and shipping. If you want medication only and no programming, RxPepsDirect gives you that for less.

Bottom line

For pure price on compounded tirzepatide, RxPepsDirect is the cheapest at $45 per 12mg vial plus a one-time $39 visit, billed through Optimal Balance Pharmacy at wholesale, and 45 to 85 percent below the Zepbound vial depending on dose. Mochi Health is the cheapest national bundle at $169 to $278. Eden holds its $199 medication price flat at every dose and owns its pharmacy. Henry Meds at $449 costs as much as the brand vial. Aspire and Nava are useful if you want tirzepatide combined with a broader peptide protocol. The regulatory picture is tighter than it was a year ago, and every legitimate service on this list depends on the same thing: a prescriber who documents a clinical reason, not a cheaper price, for the compounded version.

See RxPepsDirect tirzepatide pricing or start a $39 visit.

Clinical Evidence

The tirzepatide molecule in every compounded formulation on this list is the same 39-amino acid dual GIP/GLP-1 receptor agonist tested in the phase 3 SURPASS trials and approved by the FDA under the brand names Mounjaro (type 2 diabetes) and Zepbound (obesity). The active ingredient is identical; the difference is the carrier (B-12 or glycine) and the fulfillment pathway (503A compounding pharmacy versus branded manufacturer).

SURPASS Phase 3 Efficacy

The SURPASS clinical trial program enrolled over 10,000 patients with type 2 diabetes. At 40 weeks, tirzepatide 5mg once weekly reduced HbA1c by 1.87 to 2.07 percentage points versus placebo, and 10mg and 15mg doses achieved reductions of 2.0 to 2.5 percentage points. Weight loss at the same time point ranged from 7 to 12kg depending on dose. These results established tirzepatide as the most potent glycemic agent in the GLP-1 class and led to FDA approval of Mounjaro in May 2022 and Zepbound in November 2023.

Two-Year Outcomes in Early Type 2 Diabetes

A 2026 randomized controlled trial published in Annals of Internal Medicine compared tirzepatide to intensified conventional care in patients with early type 2 diabetes over 24 months. Patients receiving tirzepatide demonstrated superior glycemic control compared to those receiving intensified conventional therapy with multiple oral agents and insulin titration. The tirzepatide group also achieved significantly greater weight reduction at two years. These findings extend the evidence base for tirzepatide beyond the original phase 3 SURPASS trials, demonstrating durability of effect in a real-world comparator setting. The study enrolled patients within three years of type 2 diabetes diagnosis, a population that may benefit from early intensive pharmacologic intervention to preserve beta-cell function and delay microvascular complications.^[1]

Safety considerations and monitoring

Compounded tirzepatide carries the same active-ingredient safety profile as branded Mounjaro and Zepbound. The most common adverse events are gastrointestinal (nausea, diarrhea, constipation, vomiting), are usually mild to moderate, and ease over the first four to eight weeks of dose escalation. A few specific risks and drug interactions warrant closer attention, and RxPepsDirect prescribers screen for each of them during the intake consultation.

Thyroid safety and screening

The FDA-approved prescribing information for tirzepatide carries a boxed warning for thyroid C-cell tumors, based on dose-dependent tumors seen in rodent studies. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Before prescribing compounded tirzepatide, RxPepsDirect clinicians (Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC) screen for personal or family history of MTC and MEN 2; patients with these conditions are not candidates for therapy.

A 2026 retrospective analysis in Clinical Obesity followed 527 patients through 12 months of tirzepatide and found that 5.3% developed or had progression of a thyroid condition, most often nodular/goitre disease or drug-induced thyroiditis. Baseline thyroid disease and end-stage renal disease were the significant risk factors, leading the authors to recommend periodic thyroid testing for those higher-risk patients.^[2]Patients with a history of Hashimoto’s or other thyroid disease should tell their prescriber so monitoring can be arranged.

Lithium interaction

Patients maintained on lithium for bipolar disorder or other psychiatric conditions need extra caution. A 2026 case report in the Journal of Clinical Psychopharmacology documented severe lithium toxicity requiring hemodialysis in a previously stable bipolar I patient after starting tirzepatide; the mechanism is thought to involve reduced fluid intake and altered renal lithium clearance.^[3] Anyone taking lithium or another mood stabilizer should have lithium levels checked before starting tirzepatide and monitored during dose escalation, in coordination with their prescribing psychiatrist. RxPepsDirect prescribers review every current medication at intake, so tell your provider before starting therapy.

Peripheral arterial disease and limb outcomes

For patients with peripheral arterial disease (PAD), the real-world evidence is reassuring. A 2026 systematic review and meta-analysis in Diabetes Research and Clinical Practice pooled six studies covering more than 240,000 patients and found GLP-1-based therapies associated with significant reductions in major adverse limb events (HR 0.59, 95% CI 0.39-0.90) and major adverse cardiovascular events (HR 0.67, 95% CI 0.53-0.85), with the most consistent benefit in patients with diabetes.^[4]Because these are observational data, they show association rather than proof of cause. Patients with PAD or significant cardiovascular disease are evaluated individually at intake and may need additional monitoring.

Body composition and quality of life

Tirzepatide’s benefits extend past the number on the scale. A post-hoc analysis of the SURMOUNT-1 trial in the Journal of Endocrinological Investigation tracked waist-to-height ratio (WHtR), a marker of central adiposity and cardiometabolic risk. At 72 weeks, 54.7% of participants on tirzepatide 10 or 15 mg improved their WHtR category, versus 9.6% on placebo, and 16.7% reached a WHtR at or below 0.49.^[5]

Real-world quality-of-life data are more modest. A 2026 analysis of the U.S. Adelphi Real World Obesity programme in Advances in Therapy found that patients on tirzepatide reported somewhat less impairment on several health-survey and work-productivity measures than those on no obesity medication, though the differences between treatment groups were small.^[6]As an observational study, it describes associations rather than establishing that tirzepatide caused the difference.

References

1. Del Prato S, Heine RJ, Pérez Manghi FC, et al. Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial (SURPASS-EARLY). Ann Intern Med. 2026. PMID 42184419.
2. Manueli Laos EG, Serafica B, Fontaine-Nicola A, et al. Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights. Clin Obes. 2026;16(3):e70084. PMID 42145153.
3. Patarroyo-Rodriguez L, Leung J, Philbrick K, et al. Tirzepatide-Associated Lithium Toxicity Necessitating Hemodialysis in Previously Stable Bipolar I Disorder. J Clin Psychopharmacol. 2026. PMID 42227267.
4. Boccatonda A, D’Ardes D, Brighenti A, et al. GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies. Diabetes Res Clin Pract. 2026;236:113271. PMID 42009258.
5. Sattar N, Tchang BG, Vincent RP, et al. Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. J Endocrinol Invest. 2026;49(6):1237-1243. PMID 42082865.
6. Gibble TH, Leith A, Harrison L, et al. Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme. Adv Ther. 2026;43(6):2704-2721. PMID 41965443.
7. Sun XY, Jiang HL, Ma YT, et al. Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis. J Transl Med. 2026;24(1):604. PMID 42192439.
8. Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials. December 1, 2025. investor.lilly.com.
9. Novo Nordisk. Wegovy cost, coverage, and savings (self-pay pricing). NovoCare, accessed September 8, 2026. novocare.com.
10. Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron). April 1, 2026. investor.lilly.com.
11. Gallup. GLP-1 usage reaches new high. July 7, 2026. news.gallup.com.